Trials / Completed
CompletedNCT01754974
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Peginterferon alfa-2a plus Ribavirin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peginterferon Lambda-1a | |
| DRUG | Ribavirin | |
| BIOLOGICAL | Peginterferon alfa-2a |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2012-12-21
- Last updated
- 2015-01-28
Locations
16 sites across 3 countries: Czechia, Mexico, South Korea
Source: ClinicalTrials.gov record NCT01754974. Inclusion in this directory is not an endorsement.